Literature DB >> 2963229

Biochemical rationale for the synergism of 5-fluorouracil and folinic acid.

R G Moran1, K Keyomarsi.   

Abstract

The fluoropyrimidines, FUra and 5-fluoro-2'-deoxyuridine (FUdR), have been found to be more growth inhibitory and cytotoxic to both mouse and human tumor cells when grown in cell culture medium containing folinic acid. The increment in the activity of these drugs observed in folinate-containing medium was similar for a mouse leukemia cell line and for 4 human leukemia cell lines. This suggests that the mechanism of action of the fluoropyrimidines against these mouse and human cell lines is similar. The most probable mechanism of the interaction between folinic acid and the fluoropyrimidines is stabilization of thymidylate synthase (TS) in inactive complexes with 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP) and folate cofactor. Such trapping of enzyme in inactive form would negate the effects of the accumulation of the reaction substrate 2'-deoxyuridine-5'-monophosphate. It is suggested that the combination of FUra with folinic acid and, in addition, an inhibitor of ribonucleotide reductase such as hydroxyurea may be more effective than FUra and folinic acid alone.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2963229

Source DB:  PubMed          Journal:  NCI Monogr        ISSN: 0893-2751


  5 in total

Review 1.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

2.  Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study.

Authors:  E Poplin; J Roberts; M Tombs; S Grant; E Rubin
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

3.  Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.

Authors:  T L Chen; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy.

Authors:  Anna-Laura Kretz; Silvia von Karstedt; Andreas Hillenbrand; Doris Henne-Bruns; Uwe Knippschild; Anna Trauzold; Johannes Lemke
Journal:  Cancers (Basel)       Date:  2018-03-18       Impact factor: 6.639

5.  A narrative review of genetic factors affecting fluoropyrimidine toxicity.

Authors:  William H Gmeiner
Journal:  Precis Cancer Med       Date:  2021-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.